Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2). (clinicaltrials.gov) - Jul 6, 2026 - P1 | N=48 | Not yet recruiting | Sponsor: AlphaMol Science Ltd. (Shanghai)
New P1 trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|